BLOG

Discover FDA guidances for oligonucleotide bioanalysis, safety assessments, and clinical pharmacology, and how Altasciences supports regulatory-compliant drug development.

Ria Falvo, Director of Reporting and STC Committee Member, reflects on the STC’s legacy following her attendance at the 56th Annual STC Symposium.

Dr. Francesca Barone, Site Director, Altasciences, recounts highlights and notable presentations from the 2024 American College of Toxicology 45th Annual Meeting.

In Issue 7 of The Altascientist, we discuss how age, biological sex, genetics, and drug-drug interactions can affect drug metabolism and outcomes.

Discover how Altasciences reduced clinical trial start-up timelines by 70%, initiating the first dose of a Phase I MAD study in just 3.5 weeks.